Immunova Therapeutics LLC

Monrovia, CA · Biotech · Private

Self-assembled peptide nanoparticle (SAPNANO) cancer immunotherapy vaccine (IMT-001) targeting NY-ESO-1 positive cancers

Grants
$6.0M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate Cancer$1,000,000
Federal grantDepartment of Health and Human Services · Phase II · Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate Cancer$2,000,000
Federal grantDepartment of Health and Human Services · Phase II · Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate Cancer$1,000,000
Federal grantDepartment of Health and Human Services · Phase II · Development of CD4 TCR-engineered T cell immunotherapy in triple-negative breast cancer$1,001,029
Federal grantDepartment of Health and Human Services · Phase II · Development of CD4 TCR-engineered T cell immunotherapy in triple-negative breast cancer$998,971
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1577Neurocarrus Inc.——
1578ANOVAC, INC.——
1579Vesalius Therapeutics——
1580Immunova Therapeutics LLC——
1581MIMIVAX VARIA VENTURES LLC—$10M
1582PARMEDICS, INC——
1583Versa Integrated Solutions, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Synthetic T Cell Receptors For Enhancing Memory (stem) T Cells Using New Transmembranes And Signaling Domainsapplication
  • Synthetic T Cell Receptors For Enhancing Memory (stem) T Cells Using New Transmembranes And Signaling Domainsapplication
  • Synthetic T Cell Receptors For Enhancing Memory (stem) T Cells Using New Transmembranes And Signaling Domainsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.